Humanwell Healthcare (600079.SH): Duloxetine Hydrochloride Tablets Obtained Drug Registration Certificate

Humanwell Healthcare (600079.SH) announced that its subsidiary Wuhan Jiulong Renfu Pharmaceutical Co., Ltd. (referred to as "Jiulong Renfu", a subsidiary of Hubei Gedian Renfu Pharmaceutical Co., Ltd., which holds 100% of its equity) recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the Dapoxetine Hydrochloride tablets. Dapoxetine hydrochloride tablets are used to treat premature ejaculation (PE) in men. Jiulong Renfu submitted an application for marketing authorization for Dapoxetine Hydrochloride tablets to the National Medical Products Administration in July 2024 and received acceptance. As of now, the cumulative research and development investment is approximately RMB 10 million, and Jiulong Renfu has entrusted the production of Dapoxetine Hydrochloride tablets to Chongqing Boteng Pharmaceutical Co., Ltd. According to MeineNet data, the national sales of Dapoxetine Hydrochloride tablets in 2024 (including urban public hospitals, county-level public hospitals, urban pharmacies, online pharmacies) are approximately RMB 1.1 billion, with major manufacturers including Shandong Huabokai Sheng Biotechnology Co., Ltd. (produced by Yantai Luyin Pharmaceutical Co., Ltd.), Sichuan Kelun Pharmaceutical Co., Ltd., and Berlin-Chemie AG.